EXAS
Price
$45.60
Change
+$0.61 (+1.36%)
Updated
Aug 15 closing price
Capitalization
8.63B
73 days until earnings call
ILMN
Price
$100.11
Change
+$0.02 (+0.02%)
Updated
Aug 15 closing price
Capitalization
15.85B
74 days until earnings call
Interact to see
Advertisement

EXAS vs ILMN

Header iconEXAS vs ILMN Comparison
Open Charts EXAS vs ILMNBanner chart's image
Exact Sciences
Price$45.60
Change+$0.61 (+1.36%)
Volume$3.89M
Capitalization8.63B
Illumina
Price$100.11
Change+$0.02 (+0.02%)
Volume$1.53M
Capitalization15.85B
EXAS vs ILMN Comparison Chart in %
Loading...
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ILMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXAS vs. ILMN commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXAS is a Hold and ILMN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (EXAS: $45.60 vs. ILMN: $100.11)
Brand notoriety: EXAS and ILMN are both notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: EXAS: 121% vs. ILMN: 69%
Market capitalization -- EXAS: $8.63B vs. ILMN: $15.85B
EXAS [@Medical Specialties] is valued at $8.63B. ILMN’s [@Medical Specialties] market capitalization is $15.85B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $10.48B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXAS’s FA Score shows that 0 FA rating(s) are green whileILMN’s FA Score has 1 green FA rating(s).

  • EXAS’s FA Score: 0 green, 5 red.
  • ILMN’s FA Score: 1 green, 4 red.
According to our system of comparison, ILMN is a better buy in the long-term than EXAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXAS’s TA Score shows that 5 TA indicator(s) are bullish while ILMN’s TA Score has 4 bullish TA indicator(s).

  • EXAS’s TA Score: 5 bullish, 4 bearish.
  • ILMN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, EXAS is a better buy in the short-term than ILMN.

Price Growth

EXAS (@Medical Specialties) experienced а +11.25% price change this week, while ILMN (@Medical Specialties) price change was +5.87% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +2.98%. For the same industry, the average monthly price growth was +4.68%, and the average quarterly price growth was +0.72%.

Reported Earning Dates

EXAS is expected to report earnings on Oct 29, 2025.

ILMN is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Medical Specialties (+2.98% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ILMN($15.8B) has a higher market cap than EXAS($8.63B). EXAS YTD gains are higher at: -18.847 vs. ILMN (-25.084). ILMN has higher annual earnings (EBITDA): 1.78B vs. EXAS (-779.59M). ILMN has more cash in the bank: 1.16B vs. EXAS (786M). EXAS (2.52B) and ILMN (2.6B) have identical debt. ILMN has higher revenues than EXAS: ILMN (4.28B) vs EXAS (2.83B).
EXASILMNEXAS / ILMN
Capitalization8.63B15.8B55%
EBITDA-779.59M1.78B-44%
Gain YTD-18.847-25.08475%
P/E RatioN/A12.67-
Revenue2.83B4.28B66%
Total Cash786M1.16B68%
Total Debt2.52B2.6B97%
FUNDAMENTALS RATINGS
EXAS vs ILMN: Fundamental Ratings
EXAS
ILMN
OUTLOOK RATING
1..100
468
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9716
PRICE GROWTH RATING
1..100
8452
P/E GROWTH RATING
1..100
10042
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXAS's Valuation (35) in the Biotechnology industry is in the same range as ILMN (64). This means that EXAS’s stock grew similarly to ILMN’s over the last 12 months.

EXAS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ILMN (100). This means that EXAS’s stock grew similarly to ILMN’s over the last 12 months.

ILMN's SMR Rating (16) in the Biotechnology industry is significantly better than the same rating for EXAS (97). This means that ILMN’s stock grew significantly faster than EXAS’s over the last 12 months.

ILMN's Price Growth Rating (52) in the Biotechnology industry is in the same range as EXAS (84). This means that ILMN’s stock grew similarly to EXAS’s over the last 12 months.

ILMN's P/E Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for EXAS (100). This means that ILMN’s stock grew somewhat faster than EXAS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXASILMN
RSI
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
69%
Bearish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 4 days ago
76%
Bullish Trend 3 days ago
70%
MACD
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
70%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
73%
Advances
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 5 days ago
73%
Declines
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 12 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
74%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ILMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FLV73.29-0.18
-0.25%
American Century Foc Lrg Cp Val ETF
ICAP27.09-0.08
-0.28%
Infrastructure Capital Equity Income ETF
TLTW22.71-0.11
-0.48%
iShares 20+ Year Trs Bd Buywrt Stgy ETF
BLKC25.39-0.15
-0.60%
Invesco Aln Glxy Blkh Usr&Dctrzd Cmr ETF
ETHU157.51-11.86
-7.00%
2x Ether ETF

EXAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXAS has been loosely correlated with ILMN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAS jumps, then ILMN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXAS
1D Price
Change %
EXAS100%
+1.36%
ILMN - EXAS
36%
Loosely correlated
+0.02%
RVTY - EXAS
34%
Loosely correlated
+1.49%
A - EXAS
33%
Loosely correlated
+0.28%
XRAY - EXAS
33%
Poorly correlated
-0.14%
SNN - EXAS
32%
Poorly correlated
-1.15%
More

ILMN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ILMN has been loosely correlated with A. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if ILMN jumps, then A could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ILMN
1D Price
Change %
ILMN100%
+0.02%
A - ILMN
66%
Loosely correlated
+0.28%
BIO - ILMN
64%
Loosely correlated
-0.54%
RVTY - ILMN
64%
Loosely correlated
+1.49%
BRKR - ILMN
63%
Loosely correlated
-0.36%
MTD - ILMN
62%
Loosely correlated
-0.10%
More